Neurocrine Biosciences, Inc (NASDAQ: NBIX)’s stock price has plunge by 2.03relation to previous closing price of 136.69. Nevertheless, the company has seen a 8.77% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-18 that Neurocrine’s Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company’s primary revenue driver. Crenessity’s approval for CAH treatment represents a transformative opportunity. Peak sales are estimated at $1.47 billion by 2030. Neurocrine’s pipeline includes five Phase 1, six Phase 2, and two Phase 3 programs, diversifying future growth opportunities.
Is It Worth Investing in Neurocrine Biosciences, Inc (NASDAQ: NBIX) Right Now?
Neurocrine Biosciences, Inc (NASDAQ: NBIX) has a price-to-earnings ratio of 37.36x that is above its average ratio. Additionally, the 36-month beta value for NBIX is 0.35. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 8 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBIX is 98.54M and currently, short sellers hold a 3.97% ratio of that float. The average trading volume of NBIX on December 18, 2024 was 921.25K shares.
NBIX’s Market Performance
NBIX’s stock has seen a 8.77% increase for the week, with a 18.57% rise in the past month and a 15.77% gain in the past quarter. The volatility ratio for the week is 2.87%, and the volatility levels for the past 30 days are at 2.40% for Neurocrine Biosciences, Inc The simple moving average for the past 20 days is 8.75% for NBIX’s stock, with a 4.84% simple moving average for the past 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Raymond James repeating the rating for NBIX by listing it as a “Outperform.” The predicted price for NBIX in the upcoming period, according to Raymond James is $155 based on the research report published on October 10, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $159, previously predicting the price at $131. The rating they have provided for NBIX stocks is “Overweight” according to the report published on August 29th, 2024.
Wells Fargo gave a rating of “Overweight” to NBIX, setting the target price at $170 in the report published on April 24th of the current year.
NBIX Trading at 13.46% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.72% of loss for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 2.87%, as shares surge +16.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.40% upper at present.
During the last 5 trading sessions, NBIX rose by +8.34%, which changed the moving average for the period of 200-days by +3.92% in comparison to the 20-day moving average, which settled at $128.22. In addition, Neurocrine Biosciences, Inc saw 5.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from INGRID DELAET, who proposed sale 1,091 shares at the price of $133.05 back on Dec 17 ’24. After this action, INGRID DELAET now owns shares of Neurocrine Biosciences, Inc, valued at $145,158 using the latest closing price.
Onyia Jude, the Chief Scientific Officer of Neurocrine Biosciences, Inc, sale 2,331 shares at $126.29 during a trade that took place back on Nov 29 ’24, which means that Onyia Jude is holding 15,449 shares at $294,373 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc stands at 0.17. The total capital return value is set at 0.19. Equity return is now at value 16.35, with 12.09 for asset returns.
Currently, EBITDA for the company is 358.0 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 6.21. The receivables turnover for the company is 4.66for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.37.
Conclusion
In conclusion, Neurocrine Biosciences, Inc (NBIX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
